Ikena Oncology Stock Z Score
| IKNA Stock | USD 1.35 0.05 3.85% |
Ikena | Z Score |
Ikena Oncology Company Z Score Analysis
Ikena Oncology's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Ikena Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Ikena Oncology is extremely important. It helps to project a fair market value of Ikena Stock properly, considering its historical fundamentals such as Z Score. Since Ikena Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ikena Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ikena Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Ikena Oncology has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Ikena Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Ikena Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ikena Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ikena Oncology's value.| Shares | Laurion Capital Management Lp | 2023-09-30 | 534.7 K | Geode Capital Management, Llc | 2023-12-31 | 529.4 K | State Street Corporation | 2023-12-31 | 410.7 K | Vestal Point Capital Lp | 2023-12-31 | 322.7 K | Adage Capital Partners Gp Llc | 2023-12-31 | 287.9 K | Barclays Plc | 2023-12-31 | 244.7 K | Northern Trust Corp | 2023-12-31 | 238.6 K | Vida Ventures Advisors, Llc | 2023-12-31 | 225.2 K | Anson Funds Management Lp | 2023-12-31 | 209.3 K | Fmr Inc | 2023-12-31 | 4.2 M | Orbimed Advisors, Llc | 2023-12-31 | 3.5 M |
Ikena Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (33.24) % | ||||
| Current Valuation | (101.99 M) | ||||
| Shares Outstanding | 48.26 M | ||||
| Shares Owned By Insiders | 6.99 % | ||||
| Shares Owned By Institutions | 93.01 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Earning | 3.89 X | ||||
| Price To Book | 0.38 X | ||||
| Price To Sales | 7.01 X | ||||
| Revenue | 9.16 M | ||||
| Gross Profit | (48.7 M) | ||||
| EBITDA | (74.4 M) | ||||
| Net Income | (68.17 M) | ||||
| Cash And Equivalents | 192.81 M | ||||
| Cash Per Share | 5.32 X | ||||
| Total Debt | 10.74 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 6.98 X | ||||
| Book Value Per Share | 3.52 X | ||||
| Cash Flow From Operations | (79.74 M) | ||||
| Short Ratio | 3.19 X | ||||
| Earnings Per Share | (1.63) X | ||||
| Target Price | 8.33 | ||||
| Number Of Employees | 43 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 62.74 M | ||||
| Total Asset | 192.09 M | ||||
| Retained Earnings | (282.38 M) | ||||
| Working Capital | 164.46 M | ||||
| Net Asset | 192.09 M |
About Ikena Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ikena Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ikena Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ikena Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ikena Oncology Piotroski F Score and Ikena Oncology Valuation analysis. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Ikena Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.63) | Revenue Per Share 0.219 | Quarterly Revenue Growth (0.88) | Return On Assets (0.26) | Return On Equity (0.43) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.